At a glance
ClinicalIndex Comparison RecordN/ACompleted· 42 enrolled
Drug / intervention
89Zr-DFO-trastuzumab +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Trial of PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
In Brief
A clinical study evaluating 89Zr-DFO-trastuzumab and PET imaging for Esophagogastric Cancer. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The purpose of the first group (Group 1) was to find the optimal time for taking pictures after injection of 89Zr-DFO-trastuzumab, to see how long it stayed in the blood, and to see how well it was tolerated. From what the investigators have learned from Group 1, patients in Group 2 no longer need serial scans or serial blood draws. This study is based on a cohort expansion. All data is appropriately reported as there is only one study cohort
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophagogastric Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedDec 2013
Primary CompletionJun 2023
TodayJul 2026
First PostedDec 30, 2013
Enrollment StartDec 1, 2013
Primary CompletionJun 27, 2023
TodayJul 2, 2026
Enrollment to primary: 9.6 yearsPosted 12.5 years ago
Interventions
89Zr-DFO-trastuzumabradiation
PET imagingdevice